Abstract
The most important and serious neuropsychiatric disorders in Parkinson's disease (PD) are the medication-induced psychoses. They are remarkably frequent and are linked to a dopaminergic over-stimulation caused by the drugs administered over a long period of time. This complication increases the morbidity and mortality rates in PD and in the past it was very difficult to treat. Yet, the atypical antipsychotics have transformed its prognosis.We review the general pharmacology of the atypical antipsychotics, in particular clozapine and olanzapine, which we have wide experience with. We present two series in which these drugs were used with the psychosis in PD. Our studies were performed using a strict prospective methodology, with scales that are valid for psychosis, and the patients' motor signs. Both atypical antipsychotics were seen to improve the positive and negative symptoms of the patients, giving rise to no or scarce improvement of the motor signs of PD. The side effects of the two drugs were not important. Our two series are compared with others from the literature, with similar results as regards the improvements in the psychoses and the absence or only slight deterioration of Parkinson's disease.The psychoses induced by medication in PD are frequent and severe. The appearance of the atypical antipsychotics has come as a true 'revolution' in their treatment, owing to the good results obtained in the treatment of the psychoses and the scant deterioration of the motor signs of PD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.